scholarly journals Pneumothorax during Pemetrexed Treatment in a Patient with Non-Small Cell Lung Cancer: A Case Report and Literature Review

2017 ◽  
Vol 10 (2) ◽  
pp. 428-432 ◽  
Author(s):  
Yoshiro Nakahara ◽  
Shinichiro Mikura ◽  
Makoto Nagamata ◽  
Tomoya Fukui ◽  
Jiichiro Sasaki ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Stage Iv ◽  
Additional Treatment ◽  
Small Cell ◽  
Small Cell Lung ◽  
First Case ◽  
Life Threatening ◽  
Third Line

Pemetrexed is a multitargeted antifolate that has demonstrated antitumor activity in non-small cell lung cancer. A 70-year-old male presented with a stage IV non-small cell lung cancer. The patient was treated with pemetrexed as third-line chemotherapy. However, a pneumothorax occurred 16 days after the administration of the second cycle of pemetrexed. The pneumothorax was slight and the patient was observed without undergoing any additional treatment. Twenty-four days after its initial occurrence, the pneumothorax had improved. This is the first case of pneumothorax that has been observed during pemetrexed treatment. Pneumothorax during chemotherapy is rare; however, it is a life-threatening complication and should not be overlooked.

scholarly journals Successful afatinib treatment through nasogastric tube in a ventilated patient with non-small cell lung cancer

2017 ◽  
Vol 3 (4) ◽  
Author(s):  
Takahiro Karasuno ◽  
Nobuko Nishiura ◽  
Hiroyuki Takamori ◽  
Ken Kodama
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Nasogastric Tube ◽  
Kinase Inhibitors ◽  
Egfr Mutation ◽  
Stage Iv ◽  
Small Cell ◽  
Small Cell Lung ◽  
Life Threatening

<p class="BodyText1">The majority of lung cancer patients are discovered at advanced stages and some of them may often have complex medical problems in addition to the diagnosis of cancer, such as oncologic emergency requiring assistance in an intensive care unit (ICU). In the last decade, epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors have been recognized as key drugs for non-small cell lung cancer (NSCLC) harboring sensitive EGFR mutation. We report a case of stage IV NSCLC with EGFR mutation (exon 19 deletion). He was in a life-threatening stage due to a massive intrathoracic hemorrhage. After chest tube drainage and mechanical ventilation, afatinib was administered through nasogastric tube. Consequently, a dramatic response was obtained and he was able to be discharged from our hospital 11 weeks after the initiation of afatinib. This approach may be of benefit to rescue from life-threatening condition for selected patients.</p>

scholarly journals P48.11 Anlotinib Versus Chemotherapy as a Third-Line or Further Treatment for Advanced Small Cell Lung Cancer

2021 ◽  
Vol 16 (3) ◽  
pp. S504
Author(s):  
Y. Wang ◽  
X. Ling ◽  
S. Cao ◽  
J. Li ◽  
Y. Zhou ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Small Cell ◽  
Small Cell Lung ◽  
Third Line
Sign in / Sign up

Export Citation Format

Share Document